Compare Gilead Sciences, Inc. (GILD) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NICE Ltd — how do they compare? Gilead Sciences, Inc. trades at $135.61 (market cap $163.51B), while NICE Ltd trades at $100.89 (market cap $6.14B). The key difference: Gilead Sciences, Inc. is far larger — about 26.6× NICE Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| GILD | NICE | |
|---|---|---|
Market Cap | $163.51B | $6.14B |
Sector | Health | Technology |
52-Week High | $155.80 | $170.37 |
52-Week Low | $108.22 | $83.15 |
Enterprise Value | $178.05B | $5.92B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
NICE trades at $101.35, down 0.91% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.64 surpassing the $2.52 estimate. Fundamentals show robust profitability with a 65.79% gross margin and 17.57% net income margin. Recent news highlights AI-driven customer engagement expansions, including partnerships with Banco do Brasil and Sopra Steria.
The outlook remains positive with a consensus price target of $124.88, implying 23% upside. Risks include competitive pressures in AI software and potential margin compression. Analyst sentiment is bullish with 13 buys and no sells among 23 coverage firms, though technical indicators suggest near-term overbought conditions may limit immediate gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
